CNSP supply chain intelligence for CNS Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CORTICE-BIOSCIENCES-INC | CORTICE-BIOSCIENCES-INC | 92% | The Company entered into an Exclusive License Agreement with Cortice Biosciences, Inc. pursuant to which Cortice granted the Company an exclusive license to the intellectual property rights |
| ANIMAL-LIFE-SCIENCES-LLC | ANIMAL-LIFE-SCIENCES-LLC | 90% | 10.6 Sublicense Agreement between CNS Pharmaceuticals, Inc. and Animal Life Sciences, LLC. dated August 31, 2018 |
| HOUSTON-PHARMACEUTICALS-INC | HOUSTON-PHARMACEUTICALS-INC | 90% | 10.1 Amended And Restated Patent License Agreement effective as of December 28, 2017 between CNS Pharmaceuticals, Inc. and Houston Pharmaceuticals, Inc. |
| REATA-PHARMACEUTICALS-INC | REATA-PHARMACEUTICALS-INC | 90% | 10.2 Collaboration and Asset Purchase Agreement between CNS Pharmaceuticals, Inc. and Reata Pharmaceuticals, Inc. dated November 21, 2017 |
| WPD-PHARMACEUTICALS-INC | WPD-PHARMACEUTICALS-INC | 90% | 10.5 Sublicense Agreement between CNS Pharmaceuticals, Inc. and WPD Pharmaceuticals, Inc. dated August 30, 2018 |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| A-G-P-ALLIANCE-GLOBAL-PARTNERS | A-G-P-ALLIANCE-GLOBAL-PARTNERS | 90% | 10.27 Placement Agency Agreement between CNS Pharmaceuticals, Inc. and A.G.P./Alliance Global Partners |
| CORTICE-BIOSCIENCES-INC | CORTICE-BIOSCIENCES-INC | 90% | 10.25 Stock Purchase Agreement between CNS Pharmaceuticals, Inc. and Cortice Biosciences, Inc. |
| BDRX | Biodexa Pharmaceuticals Plc | 72% | Reciprocal relationship from BDRX graph: ll therapies by Vertex Pharmaceuticals, Inc. and CRISPR Therapeutics AG and SAB Biotherapeutics, Inc. is developing an immunotherapeutic. The JDRF T1D Fund ha… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| CNSP-DEBT | Debt stack $232,353 | 90% | Market cache reports total debt of $232,353. |
| CNSP-DEBT-8753 | Warrants outstanding: 0.001 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| CNSP-DEBT-8754 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| CNSP-OWNER-BANK-OF-AMERICA-CORPORATION | Bank of America Corporation | 95% | 13F/ownership overlay lists Bank of America Corporation; shares held 4; value $29; as of 2025-12-31. |
| CNSP-OWNER-UBS-GROUP-AG | UBS Group AG | 95% | 13F/ownership overlay lists UBS Group AG; shares held 729; ownership 0.09%; value $5,314; as of 2026-03-31. |
| CNSP-OWNER-IKARIAN-CAPITAL-LLC | Ikarian Capital, LLC | 95% | 13F/ownership overlay lists Ikarian Capital, LLC; shares held 45,830; ownership 5.65%; value $334,100; as of 2025-12-31. |
| CNSP-OWNER-BARRETT-COMPANY-INC | Barrett & Company, Inc. | 95% | 13F/ownership overlay lists Barrett & Company, Inc. ; shares held 8; value $58; as of 2026-03-31. |
| CNSP-OWNER-DRW-SECURITIES-LLC | DRW Securities, LLC | 95% | 13F/ownership overlay lists DRW Securities, LLC; shares held 15,429; ownership 1.90%; value $112,477; as of 2025-12-31. |
| CNSP-OWNER-STONEPINE-CAPITAL-MANAGEMENT-LLC | Stonepine Capital Management, LLC | 95% | 13F/ownership overlay lists Stonepine Capital Management, LLC; shares held 48,827; ownership 6.02%; value $355,948; as of 2025-12-31. |
| CNSP-OWNER-SOUND-INCOME-STRATEGIES-LLC | Sound Income Strategies, LLC | 95% | 13F/ownership overlay lists Sound Income Strategies, LLC; shares held 16; value $116; as of 2026-03-31. |
| CNSP-OWNER-BOOTHBAY-FUND-MANAGEMENT-LLC | Boothbay Fund Management, LLC | 95% | 13F/ownership overlay lists Boothbay Fund Management, LLC; shares held 13,524; ownership 1.67%; value $98,589; as of 2025-12-31. |
| CNSP-OWNER-DANSKE-BANK-A-S | Danske Bank A/s | 95% | 13F/ownership overlay lists Danske Bank A/s; shares held 1; value $7; as of 2025-12-31. |
| CNSP-OWNER-MAI-CAPITAL-MANAGEMENT | MAI Capital Management | 95% | 13F/ownership overlay lists MAI Capital Management; shares held 3; value $21; as of 2025-12-31. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| BDRX | Biodexa Pharmaceuticals Plc | 100.00 | 1 | ['customer'] |
| DRTS | Alpha Tau Medical Ltd. | 100.00 | 2 | |
| TLX | Telix Pharmaceuticals Limited | 100.00 | 2 | |
| TARA | Protara Therapeutics, Inc. | 50.00 | 2 | |
| CGON | CG Oncology, Inc. | 50.00 | 2 | |
| SABSW | SAB Biotherapeutics, Inc. | 50.00 | 2 | |
| CRSP | CRISPR Therapeutics AG | 50.00 | 2 | |
| COGT | Cogent Biosciences, Inc. | 50.00 | 2 | |
| GSK | GSK plc | 50.00 | 2 | |
| SABS | SAB Biotherapeutics, Inc. | 50.00 | 2 | |
| TPST | Tempest Therapeutics, Inc. | 50.00 | 2 | |
| KURA | Kura Oncology, Inc. | 50.00 | 2 | |
| PSTV | Plus Therapeutics, Inc. | 50.00 | 2 | |
| RXRX | Recursion Pharmaceuticals, Inc. | 50.00 | 2 | |
| SNDX | Syndax Pharmaceuticals, Inc. | 50.00 | 2 | |
| JNJ | Johnson & Johnson | 50.00 | 2 | |
| ATNM | Actinium Pharmaceuticals, Inc. | 38.88 | 1 | ['receiving'] |
| MNPR | Monopar Therapeutics Inc. | 14.78 | 2 |